News Feature

US funding for biodefense research continues on an upward trend, but some say the effort is misguided. Laura DeFrancesco reports.

Developing countries could exploit traditional medicine to kick-start biotech, but only if their products measure up to the demands of Western regulators. Paroma Basu reports.

Immunomodulator CTLA4-Ig was set to be the miracle drug for organ transplantation a dozen years ago, but then faded from view. Now, with startling results in rheumatoid arthritis, costimulatory blockers are on a comeback. Ken Garber reports.

Is the race to take protein kinase inhibitors to market compromising their success in the clinic?

Single-molecule sequencing may be the wave of the future, but don't count out microfluidics yet. Jim Kling reports.

Governments around the world are investing in nanotechnology in the hopes that applications in the biotechnology and chemical industry will help turn faltering economies around.

Recent setbacks in product development at PPL Therapeutics illustrate the economic challenges and regulatory uncertainties that face protein production in GM animals.